Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Andrew L. Salzman, M.D. as Kalytera’s Chief Executive Officer. Dr. Salzman will also serve as Chief Medical Officer and as a member of Kalytera’s Board of Directors.
“I am honored to lead Kalytera as we strive to advance the science of cannabinoid-based medicine,” said Dr. Salzman. “Kalytera is well positioned to positively impact the lives of patients through the development of cannabinoid and endocannabinoid-like medicines that are based on a firm scientific foundation supported by clinical evidence. I look forward to driving our development strategy, gathering the support of key physician thought leaders, and working with Kalytera’s leadership to bring novel drug candidates to the market.”
Dr. Salzman is a renowned physician, inventor, and biomedical entrepreneur who has brought numerous medicines from conception to clinical trials. As a founder, Chairman, and Chief Executive Officer of Inotek Pharmaceuticals (Nasdaq: ITEK), a clinical-stage developer of therapies for glaucoma and other serious eye diseases, Dr. Salzman raised $92M in venture capital and led a $600M licensing transaction with Genentech. Dr. Salzman has also founded and serves as Chairman of a number of biopharmaceutical firms in Israel and the U.S., including Orphan Technologies, Radikal Therapeutics, Salzman Capital Ventures, Tisbury Pharmaceuticals, Salzman Lovelace Investments, and Respirometics.
Dr. Salzman received an undergraduate degree from Yale College, a degree in medicine from Harvard Medical School, and completed a pediatric internship and residency at Columbia University Medical Center. He completed post-doctoral fellowships in pediatric infectious disease, neonatology, pediatric critical care, and mucosal immunology at the Weizmann Institute of Science in Rehovot (Israel), Boston Children’s Hospital Medical Center, Beth Israel Medical Center, and Massachusetts General Hospital. Dr. Salzman has received $102 million in federal grant funding, has authored 175 peer-reviewed scientific publications, and holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.
“Kalytera will benefit significantly from Dr. Salzman’s experience and knowledge,” said Robert Farrell, Kalytera’s President and Chief Financial Officer. “Dr. Salzman brings exceptional clinical research and development expertise and maintains strong ties to our partners in Israel. His leadership in both industry and clinical settings will be invaluable as we advance our development programs.”
“On behalf of the Kalytera team, we would like to thank Seth Yakatan for his service to the company as Interim-CEO. We recognize and appreciate Mr. Yakatan’s significant contributions to Kalytera, and we look forward to his continued participation as a member of our Board of Directors,” said David Stefansky, Co-Founder and Chairman of Kalytera’s Board of Directors.
About Andrew L. Salzman, M.D.
Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur. Dr. Salzman founded and built Inotek Pharmaceuticals, a 140-person biotech company that raised $92M in venture capital and concluded a $600M license with Genentech. As CEO of Inotek, Dr. Salzman brought numerous new chemical entities from conception to clinical stage testing, including a treatment for glaucoma that demonstrated clinical proof of concept in late Phase 2 clinical trials.
Dr. Salzman has been funded by the U.S. National Institutes of Health (“NIH”), authoring 75 federal grants and receiving $102 million in federal grant funding. In addition to 175 peer-reviewed scientific publications, Dr. Salzman holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.
Dr. Salzman received an undergraduate degree from Yale College, a degree in medicine from Harvard Medical School, and completed a pediatric internship and residency at Columbia University Medical Center. He completed post-doctoral fellowships in pediatric infectious disease, neonatology, pediatric critical care, and mucosal immunology at the Weizmann Institute of Science in Rehovot (Israel), Boston Children’s Hospital Medical Center, Beth Israel Medical Center, and Massachusetts General Hospital.
Dr. Salzman serves as Founder and Chairman of Radikal Therapeutics, Salzman Capital Ventures, Salzman Lovelace Investments, Tisbury Pharmaceuticals, and Respirometics, and is the Director of Drug Development at the Lovelace Respiratory Research Institute.
Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that we believe will address large unmet market needs. Kalytera seeks to commercialize its cannabinoid therapies across a range of disease states, with an initial focus on bone health.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.